Shares of Elanco Animal Health (NASDAQ:ELAN) have been assigned a consensus rating of “Hold” from the fifteen brokerages that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $33.56.
Several equities analysts have commented on ELAN shares. Morgan Stanley started coverage on Elanco Animal Health in a report on Wednesday, March 13th. They set an “equal weight” rating and a $34.00 price target on the stock. Bank of America upgraded Elanco Animal Health from a “neutral” rating to a “buy” rating and set a $30.95 price target on the stock in a report on Monday, March 18th. UBS Group started coverage on Elanco Animal Health in a report on Wednesday, March 20th. They set a “sell” rating and a $28.00 price target on the stock. Guggenheim started coverage on Elanco Animal Health in a report on Wednesday, May 22nd. They set a “neutral” rating on the stock. Finally, BMO Capital Markets increased their price target on Elanco Animal Health from $32.00 to $35.00 and gave the company a “market perform” rating in a report on Friday, May 10th.
ELAN stock traded down $0.22 during midday trading on Friday, hitting $34.07. 23,465 shares of the company traded hands, compared to its average volume of 6,604,176. Elanco Animal Health has a twelve month low of $28.00 and a twelve month high of $37.61. The firm’s 50 day simple moving average is $32.63.
Elanco Animal Health (NASDAQ:ELAN) last announced its quarterly earnings results on Thursday, May 9th. The company reported $0.25 EPS for the quarter, beating the consensus estimate of $0.22 by $0.03. The company had revenue of $731.10 million for the quarter, compared to analyst estimates of $743.40 million. During the same quarter last year, the business earned $0.33 EPS. The company’s revenue for the quarter was down .7% on a year-over-year basis.
In related news, Director John P. Bilbrey acquired 7,750 shares of the stock in a transaction dated Monday, May 13th. The shares were acquired at an average price of $32.39 per share, for a total transaction of $251,022.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Several institutional investors have recently made changes to their positions in ELAN. Ropes Wealth Advisors LLC acquired a new stake in shares of Elanco Animal Health in the first quarter worth $25,000. Sterling Investment Advisors Ltd. acquired a new stake in shares of Elanco Animal Health in the first quarter worth $25,000. Water Island Capital LLC acquired a new stake in shares of Elanco Animal Health in the first quarter worth $27,000. FTB Advisors Inc. acquired a new stake in shares of Elanco Animal Health in the first quarter worth $29,000. Finally, American International Group Inc. acquired a new stake in shares of Elanco Animal Health in the fourth quarter worth $48,000.
About Elanco Animal Health
There is no company description available for Elanco Animal Health Inc
Further Reading: What is a stock buyback?
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.